Crossmark

Belzutifan: a novel therapy for von Hippel–Lindau disease

Crossref DOI link: https://doi.org/10.1038/s41581-022-00544-5

Published Online: 2022-02-07

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Jingcheng http://orcid.org/0000-0002-6226-5667
Gong, Kan http://orcid.org/0000-0001-7195-677X
License Information

Text and Data Mining valid from 2022-02-07

Version of Record valid from 2022-02-07
More Information

Article History

First Online: 7 February 2022

Competing interests

: The authors declare no competing interests.